Carole Ann Bewley

7642280, Jan 5, 2010

Apr 8, 2002

10/474138

Robert C. Fahey - Del Mar CA, US
Gerald L. Newton - San Diego CA, US
Carole A. Bewley - Bethesda MD, US
Gillian Nicholas - Boulder CO, US

The Regents of the University of California - Oakland CA
National Institutes of Health - Bethesda MD

A61K 31/415
A61K 31/15
C07D 223/00
C07C 259/00

514398, 514640, 5483315, 564253

The present invention provides compounds with activity as inhibitors of acyl glucosaminylinositol amidases with amidase activity against S-conjugate amides, particularly mycothiol-derived S-conjugate amides. Certain of the invention compounds are naturally occurring compounds obtained from marine sponges and other organisms. The invention further provides methods for using the compounds to inhibit virulence and reduce antibiotic resistance of mycothiol-producing bacteria.

7964559, Jun 21, 2011

Mar 9, 2005

10/592422

Carole A. Bewley - Bethesda MD, US

The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC

A61K 38/16
B01J 20/26
C07K 14/195

514 37, 422 32, 502 7, 502403, 514 38, 514 213, 530324, 530825

The present invention relates, e. g. , to an isolated polypeptide from a cyanobacterium, , which binds specifically to an oligosaccharide comprising the tetrasaccharide Man-alpha-(1→6)Man-beta (1→4) GlcNAc-beta(1→4)GlcNAc. The polypeptide can be obtained, for example, from a cell that expresses a recombinant nucleic acid that encodes a MVL-like polypeptide. The invention also relates to an isolated polypeptide comprising one or more copies of the sequence GPLWSNXEAQXXGPX (SEQ ID NO: 1) and/or one or more copies of the sequence FTGQWXTXVEXXMSV (SEQ ID NO: 2), wherein the polypeptide binds specifically to the above-mentioned oligosaccharide. Conjugates comprising such polypeptides and an effector molecule are also disclosed, as are methods of using such polypeptides or conjugates, e. g. , for inhibiting infection by a virus, such as HIV, or for removing a virus, such as HIV, from a sample, such as a bodily fluid or an inanimate object.

8399689, Mar 19, 2013

Feb 25, 2011

13/578803

Carole A. Bewley - Bethesda MD, US
Alberto Plaza - Arlington VA, US
Jessica Keffer - Rockville MD, US

The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC

C07D 323/00
C07C 43/275
C07C 43/295

549348, 568635

Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, and methods for using the chrysophaentin compounds are disclosed. Some embodiments of the disclosed compounds are isolated from. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.

20050090643, Apr 28, 2005

Feb 25, 2003

10/505666

Carole Bewley - Bethesda MD, US

Government of the United Stateso of America, repre -resented by the Secretary, Department of Health - Rockville

A61K038/16
C07H021/04
C07K014/195
C12N001/21
C12N015/74

530350000, 514012000, 435069100, 435252300, 435320100, 536023700

A purified or isolated obligate domain-swapped dimer of CVN; an isolated or purified nucleic acid encoding at least one obligate domain-swapped dimer of CVN, optionally in the form of a vector; a host cell comprising such an isolated or purified nucleic acid; a composition comprising (i) the obligate domain-swapped dimer of CVN or the isolated or purified nucleic acid encoding at least one obligate domain-swapped dimer of CVN, optionally in the form of a vector, and (ii) a carrier therefor; a method of inhibiting a viral infection of a mammal, which method comprises administering to the mammal an antiviral effective amount of the aforementioned composition, whereupon the viral infection of the mammal is inhibited; and a method of making an obligate domain-swapped dimer of CVN, which method comprises introducing at least one mutation in the linker region of wild-type CVN, whereupon an obligate domain-swapped dimer of CVN is obtained.

20120128657, May 24, 2012

Feb 7, 2008

12/526477

Carole A. Bewley - Bethesda MD, US
Belhu B. Metaferia - Bethesda MD, US

A61K 31/395
A61K 38/43
A61K 39/395
A61K 31/704
A61K 33/24
A61K 31/422
A61K 31/437
A61K 31/519
A61K 31/57
A61K 38/50
A61P 35/00
A61P 35/02
A61P 35/04
A61P 27/02
A61P 9/10
A61P 37/06
A61P 1/00
A61P 29/00
A61P 7/06
C07D 267/00

4241301, 540456, 514450, 424 941, 514 34, 424649, 514374, 514283, 514279, 514249, 514171, 424 946

Disclosed herein are macrocyclic compounds that are effective to inhibit cell migration. In one embodiment, the compounds have the structure: or any pharmaceutically acceptable salt or solvate thereof, wherein: m is 0 or 1; R, Rand Rindependently are H, aralkyl, acyl, lower alkyl or silyl; X is —C(O)N(R)— or —C(S)N(R)—; —C(O)—; —C(S)—; Y is —OC(O)—; —OC(O)N(R)—; —N(R)C(O)—; or —OC(O)O—; G comprises a saturated or unsaturated aliphatic chain having from 2 to about 10 atoms in the chain, the chain optionally including 1, 2, or 3 heteroatoms; the chain optionally being substituted with 1, 2 or 3 substituents independently selected from lower alkyl, —OR, epoxy, aziridinyl, cyclopropyl, —NRRand halo; R, R, R, Rand Rindependently are selected from H, lower alkyl and acyl. Also disclosed are methods for making and using compounds as well as pharmaceutical compositions including one or more of the disclosed macrocycles.

20130331460, Dec 12, 2013

Feb 24, 2012

14/000761

Carole A. Bewley - Bethesda MD, US
Peter Wipf - Pittsburgh PA, US

UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV - Bethesda MD

C07C 39/373
A61K 45/06
C07C 37/14
A61K 31/055

514733, 568729

Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, methods for using the chrysophaentin compounds, and methods for synthesizing the chrysophaentin compounds are disclosed. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.